

Eli Lilly Breakfast Symposium

Meeting Room 1, Queen Sirikit National Convention Center, Bangkok

Monday, November 30, 2009

07.00 – 08.15 hr.

The new insights on ADA-EASD Consensus Statement

Chairperson: Asst. Prof. Pongamorn Bunnag (Thailand)

Speaker: Dr. Stephen Colagiuri (Australia)

It is widely known that the ADA and the EASD released a consensus statement on the medical management of hyperglycemia in Type 2 Diabetes in 2008. This consensus statement is primarily based on evidence from clinical trials plus the collective clinical judgment of the experts who participated in the exercise. The following factors were considered in the formulation of this algorithm: Effectiveness in lowering glucose, Extraglycemic effects that may reduce long-term complications (CV risk factors included hypertension and dyslipidemia), Safety profile, Tolerability, Ease of Use and Expense. The algorithm was then divided into two tiers of therapies and is made based on a stepwise progression depending on the patient's response to earlier therapy.

However, not everyone agree with aspects of this algorithm and several questions have emerged. This talk will provide some news insights into this consensus statement.